Patent 7560107 was granted and assigned to Emory University on July, 2009 by the United States Patent and Trademark Office.
Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.